Background: Inflammatory intestinal diseases are commonly encountered problems in surgical and internal medicine specialties. The uncertainty and inadequacy in both the diagnosis and treatment stages have constantly attracted the interest of investigators. Ethyl pyruvate is an agent with proven efficacy in sepsis, ischemia/reperfusion, and hemorrhagic shock studies but has not yet been put to routine use clinically. There is reason to believe that ethyl pyruvate may also be useful in the treatment of inflammatory colon diseases, which formed the basis of our study. Material and Methods: In this experimental study, we investigated ethyl pyruvate activity in a Winstar albino rat colitis model. We analyzed rats' colons to determine the effect of ethyl pyruvate as a treatment agent biochemically and pathologically. Results: Our study showed that the group treated with ethyl pyruvate before colitis induction with acetic acid had statistically significant biochemical and pathological analysis differences compared to the group without ethyl pyruvate, indicating that ethyl pyruvate is active in preventing inflammation. Conclusion: This study showed that ethyl pyruvate is effective in the acute colitis model created with acetic acid and may prevent inflammation. Other studies on the colitis model may follow on the basis of these results.